Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 8/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 5/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4890172 | 0.89 | PTGDR2 (0.38) | PTGDR2CYP2C9ENPP2CYP1A2CYP3A4 | |
| SCHEMBL13125169 | 0.86 | MEN1 (0.48) | CYP2C9CYP1A2CYP2C19MAPTTP53 | |
| SCHEMBL4718292 | 0.86 | CYP2C9 (0.48) | PTGDR2CYP2C9MAPT | |
| SCHEMBL2802517 | 0.85 | PTGDR2 (0.52) | PTGDR2CYP2C9CYP1A2CYP3A4CYP2C8 | |
| SCHEMBL4718153 | 0.85 | MAPT (0.48) | PTGDR2CYP2C9ENPP2PTGDRMAPT | |
| SCHEMBL2807725 | 0.84 | CYP2C9 (0.55) | PTGDR2CYP2C9ENPP2MAPT | |
| SCHEMBL4886371 | 0.80 | HTR2A (0.37) | PTGDR2ENPP2MAPTTP53HTR2A | |
| SCHEMBL4713432 | 0.77 | GLA (0.47) | PTGDR2PTGDR | |
| SCHEMBL4713329 | 0.75 | PLA2G7 (0.40) | PTGDR2CYP2C9CYP1A2CYP3A4CYP2C8 | |
| SCHEMBL4716119 | 0.74 | PTGDR2 (0.45) | PTGDR2CYP2C9CYP1A2CYP3A4CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2977452-A2 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | THOMAS JEFFERSON UNIVERSITY (US) | 2016-01-27 | — | — | EP | disclosed |
| EP-2977452-A2 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | THOMAS JEFFERSON UNIVERSITY (US) | 2016-01-27 | — | — | EP | disclosed |
| US-20150297597-A1 | METHODS OF TREATMENT OF SKIN ULCERS | UNIV PENNSYLVANIA (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150297597-A1 | METHODS OF TREATMENT OF SKIN ULCERS | UNIV PENNSYLVANIA (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150297597-A1 | METHODS OF TREATMENT OF SKIN ULCERS | UNIV PENNSYLVANIA (US) | 2015-10-22 | — | — | US | disclosed |
| EP-2155225-B1 | METHODS OF TREATMENT OF SKIN ULCERS | UNIV PENNSYLVANIA (US) | 2015-07-08 | — | — | EP | disclosed |
| EP-2155225-B1 | METHODS OF TREATMENT OF SKIN ULCERS | UNIV PENNSYLVANIA (US) | 2015-07-08 | — | — | EP | disclosed |
| US-20150183748-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | THOMAS JEFFERSON UNIVERSITY | 2015-07-02 | — | — | US | disclosed |
| US-20150183748-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | THOMAS JEFFERSON UNIVERSITY | 2015-07-02 | — | — | US | disclosed |
| US-9029383-B2 | Methods of treatment of skin ulcers | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-05-12 | — | — | US | disclosed |
| US-20080279846-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | THOMAS JEFFERSON UNIVERSITY (US) | 2008-11-13 | — | — | US | disclosed |
| US-20080279846-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | THOMAS JEFFERSON UNIVERSITY (US) | 2008-11-13 | — | — | US | disclosed |
| US-20080279846-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | THOMAS JEFFERSON UNIVERSITY (US) | 2008-11-13 | — | — | US | disclosed |
| US-20080103156-A1 | Bicyclic Heteroaromatic Compounds | GLAXO GROUP LIMITED (GB) | 2008-05-01 | — | — | US | disclosed |
| US-20080103156-A1 | Bicyclic Heteroaromatic Compounds | GLAXO GROUP LIMITED (GB) | 2008-05-01 | — | — | US | disclosed |
| WO-2008048867-A2 | BICYCLIC HETEROAROMATIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-04-24 | — | — | WO | disclosed |
| US-20080090851-A1 | Bicyclic Heteroaromatic Compounds | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | US | disclosed |
| US-20080090851-A1 | Bicyclic Heteroaromatic Compounds | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | US | disclosed |
| US-20080090852-A1 | Bicyclic Heteroaromatic Compounds | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | US | disclosed |
| US-20080090852-A1 | Bicyclic Heteroaromatic Compounds | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080279846-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | LPL, PLA2G1B, PLA2G2A | PTGDR2 714/4885CYP2C9 4400/4885ENPP2 38/4885 |
| US-20080090851-A1 | Bicyclic Heteroaromatic Compounds | CYP11B1, CYP46A1, CYP11B2 | PTGDR2 1572/4885CYP2C9 96/4885ENPP2 2272/4885 |
| US-20150297597-A1 | METHODS OF TREATMENT OF SKIN ULCERS | PLA2G12A, PLA2G3, PLA2G4A | PTGDR2 263/4885CYP2C9 4500/4885ENPP2 62/4885 |
| US-20080090852-A1 | Bicyclic Heteroaromatic Compounds | CYP11B1, CYP46A1, CYP11B2 | PTGDR2 1685/4885CYP2C9 93/4885ENPP2 2398/4885 |
| US-20150183748-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | LPL, LPAR1, PLA2G1B | PTGDR2 483/4885CYP2C9 4440/4885ENPP2 44/4885 |
| US-20080103156-A1 | Bicyclic Heteroaromatic Compounds | CYP11B1, CYP46A1, CYP11B2 | PTGDR2 1572/4885CYP2C9 96/4885ENPP2 2272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.